ChartAlert®

BOSCHLTD – Bosch Limited – Q4 FY26 Earnings Call – 21-May-26

Bosch’s findings imply topline resilience (8–10% base-case growth) with margin expansion (50bps) hinging on cost controls and content per vehicle, while PAT growth (10–12%) is anchored by structural initiatives but vulnerable to macro shocks.

1–2 minutes

Also see: BOSCHLTD – Bosch Limited – Q4 FY26 Financial Results – 20-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Macro stability persists; crude oil rises 10%, but supply chain agility offsets costs. Flattish volume growth is offset by content per vehicle gains (CAFE Phase 3, ADAS). JV ramps up in FY’28, contributing 2–3% to revenue. Revenue grows 8–10%, EBITDA margins expand 50bps, and PAT grows 10–12%.

ZYDUSLIFE – Zydus Lifesciences – Q4 FY26 Earnings Call – 19-May-26

Zydus Lifesciences’ topline growth hinges on specialty scaling and international momentum, while margins and cash flow are sensitive to US generics competition, acquisition execution, and capex intensity.

1–2 minutes

Also see: ZYDUSLIFE – Zydus Lifesciences – Q4 FY26 Financial Results – 19-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Management delivers on high-teens revenue growth and >24% EBITDA margins in FY27. US generics decline offset by specialty/international growth, while MedTech/Comfort Click meet guidance. Capex/working capital pressure limits FCF growth, but leverage remains <1x net debt-to-EBITDA. Biosimilar scale-up aligns with FY29–30 timeline.

DIVISLAB – Divi’s Laboratories – Q4 FY26 Financial Results – 23-May-26

Divi’s FY26 delivered topline growth with rare margin expansion in APIs, funded capex doubling via accruals on debt‑free balance sheet. Risks: ₹718 Cr inventory build — demand vs procurement clarity due H1FY27. Strong OCF, accelerating exit rate, and expanding margins keep structural case intact despite FCF compression.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 12.8% YoY (₹9,360 Cr → ₹10,560 Cr), with Q4FY26 at ₹2,831 Cr — the strongest quarter of FY26, up 9.5% over Q4FY25’s ₹2,585 Cr.
Sequential revenue momentum held: Q2→Q3→Q4 progression of ₹2,604 Cr → ₹2,604 Cr → ₹2,831 Cr signals an accelerating exit rate into FY27.
Other income jumped 44% YoY (₹352 Cr → ₹507 Cr), driven by interest on FDs; operationally irrelevant but flatters total income.

Bottomline

Net profit grew 17.2% YoY (₹2,191 Cr → ₹2,568 Cr), outpacing revenue — positive operating leverage at work.
Q4FY26 PAT of ₹751 Cr was the highest quarterly print, up 13.4% over Q4FY25’s ₹662 Cr; sequential jump from ₹583 Cr reflects Q3’s one-time labour code charge of ₹74 Cr normalising out.
Basic EPS expanded from ₹82.53 to ₹96.75 — a 17.2% YoY improvement on an unchanged share count.

Margins

EBITDA (PBT ex-other income + depreciation + finance costs): FY26 = ₹3,462 – ₹507 + ₹463 + ₹23 = ₹3,441 Cr on revenue of ₹10,560 Cr → EBITDA margin 32.6% vs FY25: ₹2,916 – ₹352 + ₹402 + ₹2 = ₹2,968 Cr on ₹9,360 Cr → 31.7%. ~90 bps expansion YoY.
Net profit margin (PAT/Revenue from ops): FY26 = 2,568/10,560 = 24.3% vs FY25 = 2,191/9,360 = 23.4%. ~90 bps improvement.
Employee costs grew 16% YoY (₹1,243 Cr → ₹1,442 Cr) and material costs grew 14.6% (₹3,821 Cr → ₹4,378 Cr net of inventory change: ₹3,821–96 = ₹3,725 Cr FY25 vs ₹4,378–285 = ₹4,093 Cr FY26, +9.9%) — cost discipline preserved margin expansion.

Growth Trajectory

Revenue CAGR trajectory: 12.8% in FY26; combined with margin expansion, the earnings growth of 17.2% YoY demonstrates operating leverage materialising at scale.
CWIP nearly doubled (₹1,022 Cr → ₹2,113 Cr) and capex was ₹2,520 Cr in FY26 vs ₹1,438 Cr in FY25 — a 75% capex step-up signals management’s confidence in sustaining double-digit volume growth.
Total equity grew from ₹14,969 Cr to ₹16,761 Cr, entirely through retained earnings; the asset base expanded from ₹16,932 Cr to ₹20,033 Cr — 18.3% in one year.

PAGEIND – Page Industries – Q4 FY26 Financial Results – 21-May-26

Page Industries’ FY26 shows structurally sound balance sheet and premium franchise, but traded‑goods mix compresses margins and inventory build in sub‑7% growth year clouds demand visibility. Q4’s 14.1% revenue growth offers re‑rating path if FY27 sustains momentum and inventory normalises into cash flow.

1–2 minutes

🔍 Observations

Topline

FY26 revenue grew 6.3% YoY (₹4,93,491L → ₹5,24,678L), modest for a premium innerwear franchise but directionally intact.
Q4FY26 revenue jumped 14.1% YoY (₹1,09,807L → ₹1,25,260L), signalling a strong close to the year.
Traded goods purchases surged 56% YoY (₹73,771L → ₹1,15,161L), indicating a significant mix shift toward outsourced/traded inventory.

Bottomline

FY26 net profit grew 4.8% YoY (₹72,914L → ₹76,382L), lagging revenue growth — cost pressures compressed operating leverage.
Q4FY26 PAT of ₹17,873L grew 9.0% YoY (vs ₹16,401L), a cleaner quarter absent the Q3 exceptional charge.
EPS expanded from ₹653.71 to ₹684.81, a 4.8% YoY gain on flat share capital — purely earnings-driven.

Margins

FY26 EBITDA (PBT + Finance costs + D&A): ₹1,02,534L + ₹4,978L + ₹10,663L = ₹1,18,175L on revenue of ₹5,24,678L → EBITDA margin of 22.5% vs FY25: ₹97,858L + ₹4,638L + ₹9,923L = ₹1,12,419L on ₹4,93,491L → 22.8%. Marginal 30bps compression.
Net profit margin: FY26 = ₹76,382L / ₹5,24,678L = 14.6% vs FY25 = ₹72,914L / ₹4,93,491L = 14.8%. Stable but gently declining.
Employee costs rose 14.8% YoY (₹82,150L → ₹94,294L), growing materially faster than revenue — the primary margin drag.

Growth Trajectory

6.3% topline growth is below historical norms for Page Industries; the traded goods surge suggests channel/product mix changes rather than organic volume acceleration.
Q4 quarterly trend (14.1% YoY) is the strongest quarter of FY26 — momentum is improving into the new year.
Inventory build of ₹19,679L (cash flow basis) in a 6%-growth year is a caution flag on demand visibility.

APOLLOHOSP – Apollo Hospitals Enterprise – Q4 FY26 Earnings Call – 21-May-26

Findings imply APOLLOHOSP/ Apollo Hospitals’ resilient topline growth (10–15%) with margin stability (EBITDA ±20–50 bps) but high sensitivity to macroeconomic and regulatory risks.

1–2 minutes

Also see: APOLLOHOSP – Apollo Hospitals Enterprise – Q4 FY26 Financial Results – 20-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

FY27 delivers 12–15% volume growth and 20–25 bps margin expansion, supported by stable macroeconomic conditions and execution of capex plans. Free cash flow remains robust, funding dividends and debt reduction. Key variables: Inflation at 5–6%, no major regulatory shocks.

ITC – ITC Limited – Q4 FY26 Investor Presentation – 21-May-26

ITC’s topline resilience hinges on FMCG-Others and NewGen channels, while bottomline and margins face structural pressure from taxation, illicit trade, and input costs.

1–2 minutes

Also see: ITC – ITC Limited – Q4 FY26 Financial Results – 21-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Tax hikes partially offset by pricing, but illicit trade captures 5-10% volume. Agri remains subdued due to geopolitical risks, while FMCG-Others sustains 10% revenue growth. EBITDA grows 5-7% YoY, with margins stable but compressed in Cigarettes/Paperboards.

BEL – Bharat Electronics – Q4 FY26 Earnings Call – 20-May-26

BEL/ Bharat Electronics’ topline resilience hinges on order execution (QRSAM/P-75I); margins remain robust (>28%) if indigenization offsets cost inflation, but cash flow conversion and working capital are key watchpoints.

1–2 minutes

Also see: BEL – Bharat Electronics – Q4 FY26 Financial Results – 19-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

QRSAM signs by Jun-2026, but P-75I slips to FY28; order inflow at ~INR 50,000 cr. EBITDA margins sustain at 28–29% (wage/semiconductor offsets indigenization gains). Revenue grows 15–16%, with cash conversion improving to 25%. Non-defense/export contribute 10–12% of revenue.

AMBER – Amber Enterprises – Q4 FY26 Earnings Call – 18-May-26

AMBER/ Amber Enterprises’ topline growth remains robust (20%+ base case), but margin compression (50–100 bps) and working capital strain are near-term headwinds; long-term PCB leadership and Railway order book underpin structural upside.

1–2 minutes

Also see: AMBER – Amber Enterprises – Q4 FY26 Financial Results – 16-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Commodity inflation stabilizes (no further spikes), RDSO approvals on time, RAC industry grows 12–13%.
FY27 revenue grows ~20% (Electronics +40%, Railway +30%, Consumer Durables +12%). Margins compress 50–100 bps (partial pass-through). Net debt at INR 700–800 crores; capex cash outflow INR 1,100–1,200 crores. Ascent-K trial production Q3 FY28.

JSWSTEEL – JSW Steel – Q4 FY26 Earnings Call – 14-May-26

JSW Steel’s topline grows 10–14% CAGR (demand + capacity), bottomline leverages operating leverage + deleveraging, while margins remain resilient (18–22%) but sensitive to raw material costs and execution risks.

1–2 minutes

Also see: JSWSTEEL – JSW Steel – Q4 FY26 Financial Results – 14-May-26

3-Scenario Framework

📊 Base Case (60% Probability)

Key Variables: Domestic demand grows 7–9% (FY27), capex execution on track, coking coal costs stabilize at +$12–15/tonne.
Outcome: Revenue CAGR ~10%, EBITDA margins sustain at 18–20%, net debt/EBITDA <2.5x. 62M tonnes capacity by FY32 supports market share gains in flat steel. JV contributions (16M tonnes) accelerate growth without overleveraging.

KPIGREEN – KPI Green Energy – Q4 FY26 Earnings Call – 12-May-26

KPIGREEN/ KPI Green Energy’s topline growth (40–50% CAGR) hinges on IPP execution and BESS scaling, while margins (33–36% EBITDA) depend on IPP-CPP mix optimization—bottomline resilience requires curtailing interest burden via phase-wise commissioning.

1–2 minutes

Also see: KPIGREEN – KPI Green Energy – Q4 FY26 Financial Results – 6-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: IPP additions at 1.2–1.5 GW/year, BESS margins at 15–18%, EPC order book sustains 40–50% growth.
Outcome: Revenue/PAT CAGR 40–45%, EBITDA margins stable at 33–36%, ROE recovers to 16–18% by FY28. Promoter pledge released by March’27; curtailment risks partially mitigated by green corridors.